Clinical trial · Interventional
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
NCT00029029CI-TRIAL-00046578completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells and may help to relieve pain caused by bone metastases. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in relieving pain in patients who have bone metastases.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pain therapy | Procedure | — | UNRESOLVED |
| radiofrequency ablation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed bone metastases * Pain refractory to non-opioid analgesic medication and radiotherapy OR * Patient is considered a poor candidate for opioid analgesics or radiotherapy * Initial worst pain score within the past 24 hours at least 4 on a scale of 0-10 * Tumors deemed accessible for radiofrequency ablation * No evidence of impending fracture in weight-bearing bones (more than 50% loss of cortical bone) * Tumors must be more than 1 cm from critical structures including: * Spinal cord, brain, or other critical nerve structures * Large abdominal vessel (e.g., aorta or inferior vena cava) * Bowel or bladder PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Not specified Life expectancy: * More than 2 months Hematopoietic: * Platelet count at least 75,000/mm3 Hepatic: * INR less than 1.5 Renal: * Not specified Other: * Not pregnant or nursing * Negative pregnancy test PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 3 weeks since prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 3 weeks since prior radiotherapy Surgery: * Not specified Other: * At least 3 days since prior aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs * No concurrent anticoagulants
References
Publications (0)
Data not yet available
No reference posted for this study.